Answers are grounded in this paper and cite their sources.
Review details the role of NaV 1.8 selective agonist suzetrigine in managing chronic pain, highlighting pharmacologic impact.
Voltage-gated sodium channels are integral for various physiologic processes including neurological signaling and cardiac contractility in humans. Classically a target to regulate cardiac arrhythmias, sodium channel agonists have held special interest as pharmacologic targets for pain management. However, the lack of receptor selectivity and specificity have resulted in various unwanted side effects and limited therapeutic ranges for nonspecific sodium channel agonists. Recently, suzetrigine, a voltage gated sodium channel subtype (NaV 1.8) selective agonist has been released and utilized for acute pain management with promising results. In this manuscript we highlight the physiology and pathology of voltage gated sodium channels along with current pharmacologic options in regards to its potential role for chronic pain management.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: